Robert Hopfner
Managing Partner @ Pivotal bioVenture Partners
San Francisco, United States
Robert Hopfner is a Series B investor at Pivotal bioVenture Partners in San Francisco focused on Biotechnology and Health Care. Robert Lorne Hopfner is based out of San Francisco, California and is the Managing Partner of Pivotal bioVenture Partners. Robert previously worked at Bay City Capital as a Managing Director. Robert Lorne Hopfner attended the University of Saskatchewan. Robert Lorne Hopfner has been received the Governor General of Canada Gold Medal Award.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 42%
Last updated:
For AI agents: llms.txt
Industries Robert Hopfner invests in
Stages Robert Hopfner invests in
Countries Robert Hopfner invests in
Investment Focus
Industry
- Biotechnology 7 (58%)
- Health Care 6 (50%)
- Therapeutics 4 (33%)
- Biopharma 3 (25%)
- Pharmaceutical 3 (25%)
Stage
- Series B 4 (33%)
- Series C 4 (33%)
- Series A 3 (25%)
- Post-IPO Equity 1 (8%)
Country
- United States 6 (50%)
- Iceland 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Evommune
|
Evommune is taking a tissue-based approach to insights and accelerating the development of transformative medicines for inflammatory diseases. Evommune creates novel strategies to treat inflammatory disorders by developing treatments that address symptoms while also halting disease progression. Evommune's pipeline contains initiatives aimed atcombating highly prevalent inflammatory illnesses. Its mission is to drive real advancements for patients suffering from these diseases, with all of its programs designed to produce best-in-class profiles. | $115M / Series C / Oct 31, 2024 | |
|
Evommune
|
Evommune is taking a tissue-based approach to insights and accelerating the development of transformative medicines for inflammatory diseases. Evommune creates novel strategies to treat inflammatory disorders by developing treatments that address symptoms while also halting disease progression. Evommune's pipeline contains initiatives aimed atcombating highly prevalent inflammatory illnesses. Its mission is to drive real advancements for patients suffering from these diseases, with all of its programs designed to produce best-in-class profiles. | $50M / Series B / Apr 26, 2023 | |
Oculis
|
The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $91M / Post-IPO Equity / Mar 03, 2023 | |
Plexium
|
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases. Plexium's platform focuses on the discovery of next-generation TPD drugs that extend beyond the limited applications of Proteolysis Targeting Chimeras (PROTACs) and cereblon imids, unraveling the boundless possibilities of truedrug-like protein degraders. From molecular glues to monovalent degraders, the possibilities are endless across a wide variety of therapeutic areas. | $102M / Series B / Feb 23, 2022 | |
|
Evommune
|
Evommune is taking a tissue-based approach to insights and accelerating the development of transformative medicines for inflammatory diseases. Evommune creates novel strategies to treat inflammatory disorders by developing treatments that address symptoms while also halting disease progression. Evommune's pipeline contains initiatives aimed atcombating highly prevalent inflammatory illnesses. Its mission is to drive real advancements for patients suffering from these diseases, with all of its programs designed to produce best-in-class profiles. | $83M / Series A / Sep 09, 2021 | |
|
Oculis
|
The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $57M / Series C / May 04, 2021 | |
|
Plexium
|
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases. Plexium's platform focuses on the discovery of next-generation TPD drugs that extend beyond the limited applications of Proteolysis Targeting Chimeras (PROTACs) and cereblon imids, unraveling the boundless possibilities of truedrug-like protein degraders. From molecular glues to monovalent degraders, the possibilities are endless across a wide variety of therapeutic areas. | $35M / Series A / Jan 19, 2021 | |
Rallybio
|
Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areasof hematology, immuno-inflammation, maternal fetal health and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. | $145M / Series B / Apr 14, 2020 | |
Inozyme
|
Inozyme is a provider of therapies for rare diseases of calcification affecting soft tissues and bone created to offer potentially disease-modifying therapies to help children who are affected with rare, but severe and debilitating disorders of metabolism. The company's enzyme replacement therapy provides the treatment of Generalized ArterialCalcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2), enabling patients to treat diseases characterized by mineral imbalances in the body. | $67.4M / Series A / Apr 10, 2019 | |
|
Oculis
|
The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $23.3M / Series B / Jan 04, 2018 | |
| See all 12 investments → | |||
Co-Investors
About Pivotal bioVenture Partners
Pivotal bioVenture Partners is a $300 million life sciences venture capital fund established in 2017. They invest in privately held North American and European companies focused on innovative therapeutic products and platforms to address major unmet medical needs. They invest at all stages in a company’s evolution, from company creation through midand late stage clinical development. Their team brings diverse experience in venture capital, company building, and drug discovery and development to the table in working with entrepreneurs to advance their businesses.
Pivotal bioVenture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Ash Khanna
Partner, Board Member HotSpot Tx, Bolt Bio, Fountain Tx and Evommune
|
|||
Heather Preston
Managing Partner
|
|||
Jeni Lee
Partner
|
|||
|
Robert Hopfner
Managing Partner
|
|||
|
Vincent Cheung
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Robert Hopfner invest in?
Robert Hopfner invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Robert Hopfner last invest?
The most recent investment recorded for Robert Hopfner closed in Oct 2024. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
